| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T270 |
0-37 |
Sentence |
denotes |
Anakinra Antagonist of IL-1 receptor. |
| T271 |
38-294 |
Sentence |
denotes |
IL-1 is one of the main drivers of immunologic response and symptoms in patients with cytokine-release syndrome. • Not available • Comparison of anakinra vs. emapalumab (anti–interferon γ monoclonal antibody) vs. standard of care in patients with COVID-19. |
| T272 |
295-344 |
Sentence |
denotes |
Open-label RCT (NCT04324021, not yet recruiting). |
| T273 |
345-391 |
Sentence |
denotes |
Primary endpoint: treatment success at day 15. |
| T274 |
392-593 |
Sentence |
denotes |
• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. |
| T275 |
594-643 |
Sentence |
denotes |
Open-label RCT (NCT04330638, not yet recruiting). |
| T276 |
644-711 |
Sentence |
denotes |
Primary endpoint: time to clinical improvement (follow-up 15 days). |
